(Q28678663)
Statements
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects (English)
Patricia St Clair
Mark X Sliwkowski
Michael G Brattain
1 April 2004
64
7